Class: 5α-Reductase Inhibitor
Dosage Forms. Capsule: 0.5 mg
Common FDA Label Indication, Dosing, and Titration.
1. Benign prostatic hyperplasia: 0.5 mg po daily
1. Male pattern alopecia: 0.5 mg po daily
2. Prostate cancer prevention: 0.5 mg po daily
MOA. Dutasteride inhibits the conversion of testosterone to 5α-dihydrotestosterone (DHT) by 5α-reducatse, isoform 1 and 2.
Drug Characteristics: Dutasteride
Medication Safety Issues: Dutasteride
Drug Interactions: Dutasteride
Adverse Reactions: Dutasteride
Efficacy Monitoring Parameters. American Urologic Association (AUA) Symptom Score, decrease in residual urine volume, increased urinary flow, increased hair growth.
Toxicity Monitoring Parameters. Shortness of breath, skin rash, swelling.
Key Patient Counseling Points. Symptoms may not improve for up to 6 mo after starting treatment. Do not donate blood while taking or for 6 mo after stopping dutasteride, as it may be transfused to a pregnant woman. Women who are pregnant or may become pregnant should avoid touching or handling this medicine. This medicine can get into the body through the skin and may prevent development of genitalia in an unborn male baby.
Clinical Pearls. May be combined with the alpha-blocker tamulosin for the treatment of BPH. Draw baseline PSA before initiating therapy. Note that PSA will decrease by 50% with treatment; double PSA values when assessing for prostate cancer.